News Daily News Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive Michael O'Riordan September 09, 2022
News Conference News ESC 2022 ESC Revamps Guidelines on Ventricular Arrhythmias, Sudden Cardiac Death Todd Neale September 02, 2022
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for August 2022 Shelley Wood September 01, 2022
News Conference News ESC 2022 DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum Todd Neale August 27, 2022
News Conference News ESC 2022 EchoNet AI Algorithm Beats Sonographers for Estimating LV Function Shelley Wood August 27, 2022
News Conference News ESC 2022 PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2 Michael O'Riordan August 27, 2022
News Daily News Antibiotics Before Invasive Dental Work Helpful in High-Risk Patients Caitlin E. Cox August 22, 2022
News Daily News After COVID-19, Unvaccinated at Risk for Long-term CVD Complications Michael O'Riordan August 16, 2022
News Daily News ‘Stunning’ Lack of Data on CV Issues in Pregnant Women With COVID-19 L.A. McKeown August 10, 2022
News Daily News Early LV Recovery After TAVI Points to Better 5-Year Survival Yael L. Maxwell August 01, 2022
News Daily News Shock in Peripartum Cardiomyopathy Especially Risky in Black, Hispanic Patients Caitlin E. Cox July 13, 2022
News Daily News LVEF Analysis Digs Anew Into Revascularization Benefits in Ischemic CAD Michael O'Riordan July 11, 2022
News Daily News Grieving a Loved One Increases Mortality Risk in HF Patients L.A. McKeown July 06, 2022
News Features As US Abortion Protections Are Lost, Cardiologists Brace for Impact Todd Neale June 24, 2022
Presentation TVT 2022 Percutaneous Intramyocardial Septal Radiofrequency Ablation (PIMSRA) for Hypertrophic Obstructive Cardiomyopathy: Results From the First 200 Patients Presenter: David Hsi June 09, 2022
News Daily News Following Takotsubo, Men Have Worse Outcomes, Are More Likely to Die Than Women Yael L. Maxwell June 03, 2022
News Conference News ESC Heart Failure 2022 Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE Todd Neale May 31, 2022